Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Beigene Ltd Ads (NQ: BGNE)
157.68 USD  -6.32 (-3.85%)
Official Closing Price  /  Updated: 4:33 PM EDT, Aug 15, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 451,775
Open 162.31
Bid (Size) 155.00 (1)
Ask (Size) 164.00 (1)
Prev. Close 164.00
Today's Range 156.68 - 163.37
52wk Range 65.58 - 220.10
Shares Outstanding 53,760,296
Dividend Yield N/A
Performance
YTD
+56.41%
+56.41%
1 Month
-3.38%
-3.38%
3 Month
-13.60%
-13.60%
6 Month
+22.01%
+22.01%
1 Year
+125.35%
+125.35%
Top News
More News
BeiGene Reports Second Quarter 2018 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the... Read More
from GlobeNewswire News Releases
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the... Read More
from PR Newswire
More News
Read More
BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
from GlobeNewswire News Releases
BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
from GlobeNewswire News Releases
BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering
from GlobeNewswire News Releases
BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in Chin
from GlobeNewswire News Releases
BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer
from GlobeNewswire News Releases
BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM)
from GlobeNewswire News Releases
New ETF allows you to invest in up-and-coming Chinese biotech companies
category BGNE , Medical Products , HK:0874 , and 16 more.
from MarketWatch
The 3 Hottest Insider Trading Stocks Right Now
category Stocks / Equities
from Blogs - TalkMarkets
Hong Kong stocks can't escape US-China trade war's 'very long shadow'
category Markets , Economics/Economy (Global) , Places/Asia , and 15 more.
from CNBC.com News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.